Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo.

@article{Zinonos2011AnticancerEO,
  title={Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo.},
  author={Irene Zinonos and Agatha Labrinidis and Michelle S. Lee and Vasilios Liapis and Shelley J Hay and Vladimir Ponomarev and Peter Diamond and David M. Findlay and Andrew C W Zannettino and Andreas Evdokiou},
  journal={Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research},
  year={2011},
  volume={26 3},
  pages={630-43}
}
Osteoprotegerin (OPG) is a secreted member of the tumor necrosis factor (TNF) receptor superfamily that binds to the ligand for receptor activator of nuclear factor κB (RANKL) and inhibits bone resorption. OPG can also bind and inhibit the activity of the TNF-related apoptosis-inducing ligand (Apo2L/TRAIL), raising the possibility that the anticancer efficacy of soluble Apo2L/TRAIL may be abrogated in the bone microenvironment where OPG expression is high. In this study we used a murine model… CONTINUE READING